Cenisertib (also known as R763) is water-soluble, synthetic small molecule aurora kinase inhibitor with potential antineoplastic activity. Cenisertib is a potent adenine triphosphate-competitive inhibitor of Aurora kinase isoforms A–C, disrupting mitotic spindle activity, blocking cell separation, and leading to polyploidy and cell death. At low nanomolar concentrations, Cenisertib also inhibits other kinases involved in cell survival and proliferation including FLT3, BCR-ABL1, and BCR-ABL1 with T315I mutation. It also inhibits JAK2 kinase, but at higher concentrations. Preclinically, Cenisertib has demonstrated potent antitumor activity as a single agent and in combination treatment in leukemia cell lines, freshly isolated leukemia cells, and leukemia xenograft models. Toxicities appear to be related mainly to the gastrointestinal and hematopoietic systems. In animal models, activity and toxicity depend not only on dose but also on the schedule of administration.

GM-602 (GM6) is a six-amino-acid active analog peptide of Motoneuronotrophic factor (MNTF). This compound is a small peptide that can cross the blood-brain barrier and has been shown to induce an embryonic-like neuroprotective microenvironment that helps detect and self-correct CNS- and neurodegenerative-related pathophysiology. Phase II clinical trials with GM-602, GM-604 and GM-608 have been completed to examine its potential in respectively stroke, Amyotrophic Lateral Sclerosis (ALS), and Parkinson’s disease.

Avelestat, also known as AZD9668, is a novel, oral inhibitor of neutrophil elastase (NE), an enzyme implicated in the signs, symptoms, and disease progression in NE-driven respiratory diseases such as bronchiectasis, Cystic Fibrosis and chronic obstructive pulmonary disease via its role in the inflammatory process, mucus overproduction, and lung tissue damage. Its development was discontinued due to unknown reasons. Nevertheless, this drug in the phase II of clinical trial as adjunctive therapy in improving insulin sensitivity of insulin-resistant type 2 diabetic subjects. The drug's clinical profile suggests that it will be well tolerated with few, if any, side effects, and the existence of simple methods that can indirectly measure its activity in vivo.

Aganepag isopropyl, an IOP-lowering agent, is an antiglaucoma agent. It is a selective EP2 receptor agonist.

Suncillin is an antibacteria and antifungal agent produced in Phytera's laboratory from a cell culture of a plant. Suncillin was patented by Bristol-Myers Co. In 1968 for the Pseudomonas bacteria treatment but was never marketed.

Ezlopitant (CJ-11974) is a non-peptide neurokinin-1 receptor antagonist. Pfizer was developing ezlopitant for the potential treatment of irritable bowel syndrome and chemotherapy-induced emesis. Development of ezlopitant has been discontinued.

Cypenamine (2-phenylcyclopentylamine) is a psychostimulant and antidepressant drug developed at William S. Merrell Chemical Company.

Pyridiphenthion (also known as Pyridaphenthion) is dialkyl pyridazinonyl thiophosphate derivative patented by American Cyanamid Co. as insecticides. Pyridiphenthion acts as broad-spectrum insecticide and acaricide used in the control of sucking and chewing insects and spider mites in cereals, vegetables, fruits and ornamental crops. In Spain and in other countries, it is used in rice fields for the control of Chilo supressalis by aerial application and could contaminate Mediterranean wetlands like Albufera Natural Park